Ceremorphic Adds Industry Veterans in Life Sciences and Semiconductors to its Board of DirectorsJune 29, 2023
Suresh Katta and Camillo Martino bring valuable expertise as Ceremorphic enters its next phase of growth and expansion as demand for energy-efficient AI supercomputing accelerates.
SAN JOSE, Calif.–(BUSINESS WIRE)–Ceremorphic, a fabless silicon and system development company, today announced the addition of two key industry experts on its board of directors to strengthen its position and speed product deployments in both the datacenter and life sciences markets. New appointments include Suresh Katta, a successful entrepreneur and founder and CEO of Saama Technologies, as well as Camillo Martino, a semiconductor veteran who has been CEO and C-suite executive in a number of high growth technology companies.
“Ceremorphic is on track to deliver century defining innovations in energy-efficient AI supercomputing, and the addition of Suresh and Camillo will be instrumental in driving our next wave of expansion,” said Dr. Venkat Mattela, Founder and CEO of Ceremorphic. “Suresh brings extensive experience in Lifesciences to propel our Biocompute Datacenter system architecture technology into the AI drug discovery field. Likewise, Camillo has vast experience in the semiconductor industry with a proven history of growing businesses and developing longer term strategies, which will be key as Ceremorphic continues to solve today’s most challenging supercomputing problems.”
About Suresh Katta
“Ceremorphic has a world-class engineering team backed by an arsenal of patents that can truly redefine the methodology of AI drug discovery going forward,” said Suresh Katta. “I am looking forward to working with the company’s Board and Executives to usher in this new computing paradigm and achieve transformational change.”
As the founder of Saama Technologies in 2007, Suresh has successfully leveraged AI to reshape businesses across different verticals, including a significant contribution in life sciences. In June 2022, Suresh was elevated to Chairman Emeritus of Saama’s Board, following his leadership in stewarding Saama’s partnership with Pfizer to develop the world’s first COVID-19 vaccine in less than one year. In 2021, he architected a bold new strategic growth investment for Saama with global investment firm Carlyle and a unique consortium of the corporate venture arms of major pharmaceutical companies, including Pfizer, Merck, Amgen, and McKesson.
As one of the world’s most inspiring data & analytics (D&A) innovators, Suresh serves on the Board of Directors of OneCell Diagnostics, a genomics-based Precision Oncology company providing comprehensive genomic solutions for better cancer management, as well as The Stimson Center, which promotes international security and shared prosperity through applied research and independent analysis, global engagement, and policy innovation. Previously, Suresh served on the Board of Directors of the Association of Clinical Research Organizations (ACRO), advocating for safe, ethical clinical trials that protect patients and ensure high-quality results. In recognition of his contributions, Suresh was named PM360’s 2018 ELITE Entrepreneur and one of PharmaVOICE’s 100 Most Inspirational Leaders. He frequently contributes to industry publications and is a sought-after featured speaker for industry conferences and panels. Prior to founding Saama, Suresh successfully launched two startups.
Suresh holds Honorary Doctorate degrees from Ajeenkya DY Patil University and MIT ADT University, both in Pune, India. He received a Master of Science in Computer Engineering from University of Louisiana at Lafayette, and a Bachelor of Science in Electrical and Electronics Engineering from RV College of Engineering.
About Camillo Martino
“The compute and energy requirements for applications such as generative AI have become insurmountable, requiring a new system architecture built from the ground up,” said Camillo Martino. “With its leadership team, engineering expertise and technology portfolio, the Ceremorphic team is uniquely positioned to deliver this new architecture and I look forward to being a part of this industry-leading innovation.”
Camillo Martino is a semiconductor veteran and currently serves as a board member and executive advisor to multiple technology companies. Camillo is currently the Chair of the Board of Directors of Magnachip (MX) and has served as a member of its Board since 2016. He has also been a Board Member of CXApp (CXAI) since 2020 and Sensera (SE1) since 2018. Camillo also serves on the Board of Directors at multiple privately held companies, including VVDN Technologies and Sakuu.
Previously, Camillo served as a member of the Board of Directors at Cypress Semiconductor (CY) from June 2017 through to the sale of the company to Infineon in April 2020. He also served as a Director of Moschip Technologies (BOM: 532407) from 2017 to 2019, and as a director and CEO of Silicon Image, Inc., a global semiconductor company, from January 2010 until the completion of its sale to Lattice Semiconductor Corporation in March 2015. From 2008 to 2009, Camillo served as chief operating officer of SAI Technology Inc., and also as a director from 2007 to 2010. From 2005 to 2007, he served as the CEO and director of Cornice Inc., and from 2001 to 2005, he served as the executive vice president and chief operating officer at Zoran Corporation, a global semiconductor company. Prior to that, Camillo held multiple positions with National Semiconductor Corporation for a total of nearly 14 years in four countries.
Camillo holds a Bachelor of Applied Science from the University of Melbourne and a Graduate Diploma (in Digital Communications) from Monash University in Australia.
Founded in April 2020, Ceremorphic currently has 160 full-time employees dedicated to solving the compute performance and energy efficiency requirements of AI supercomputing and Generative AI. Leveraging more than 200 patents and proven expertise in creating industry-leading silicon and system products, Ceremorphic has developed a ground-up architecture with century defining innovations that will transform both computing and life sciences fields. The company develops advanced system products based on its own silicon in TSMC 5nm and 3nm process nodes. For more information, visit https://www.ceremorphic.com.
Copyright 2023. All rights reserved. Ceremorphic is a registered trademark of Ceremorphic, Inc.